CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

This quarterly report represents an earnings surprise of +40.00%. A quarter ago, it was expected that this pharmaceutical and medical device company would post earnings of $0.25 per share when it actually produced earnings of $0.3, delivering a surprise of +20%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. CorMedix, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $39.74 million for the quarter ended June 2025, surpassing ...